

1 **Supplementary information for**

2

3 **NudCL2 is required for cytokinesis by stabilizing RCC2 with Hsp90 at the**  
4 **midbody**

5

6

7 Xiaoyang Xu<sup>1,#</sup>, Yuliang Huang<sup>1,#</sup>, Feng Yang<sup>2</sup>, Xiaoxia Sun<sup>1</sup>, Rijin Lin<sup>1</sup>, Jiaying Feng<sup>1</sup>,  
8 Mingyang Yang<sup>1</sup>, Jiaqi Shao<sup>1</sup>, Xiaoqi Liu<sup>3</sup>, Tianhua Zhou<sup>1,4,5,\*</sup>, Shanshan Xie<sup>6,\*</sup> and  
9 Yuehong Yang<sup>1,4,\*</sup>

10

11

12

13 Corresponding authors:

14 yhyang@zju.edu.cn (Y. Yang);

15 sxie@zju.edu.cn (S. Xie);

16 tzhou@zju.edu.cn (T. Zhou)

17

18

19 **This PDF file includes:**

20 Figures S1 to S9

21 Table S1

22 Legends for Datasets S1 to S2

23

24 **Other supporting materials for this manuscript include the following:**

25 Movie S1-S13

26 Datasets S1 to S2

27


A

WT           ATTGAAGTTCAGGTGCCGCCAGGCACGCGCGCCCAGGATATCC


KO-1           ATTGAAGTTCAGGTGCCGCCAGGCACGCGCGCCCAGGATATCC   1bp insertion

KO-2 { allele 1 ATTGAAGTTCAGGTGCCGCCAGGCACGCGCGCCCAGGATATCC   1bp insertion  
      allele 2 ATTGAAGTTCAGGTGCC-----CAGGATATCC   16bp deletion

B



C




28

29 **Figure S1 (related to Figure 1). Deletion of NudCL2 leads to cytokinesis failure**

30 (A) Indel mutation of the *NudCL2* DNA locus in *NudCL2* knockout (KO) cells. The  
31 sgRNA target site (underlined) is indicated in red. The PAM (protospacer adjacent  
32 motif) site is indicated in orange. TA cloning of PCR products from genomic DNA  
33 extracted from WT and *NudCL2* KO cells. The green texts indicate base mutation  
34 (deletion or insertion) in the knockout cells. (B) Control and *NudCL2* KO HEK-293  
35 cells were stained with the DNA-specific dye Hoechst 33342 for 15 minutes and  
36 subjected to time-lapse experiments. DIC stills of the live cell imaging experiment of  
37 the control or *NudCL2* KO cells. Time point 00:00 (hours:minutes) refers to the first  
38 frame where the separating sisters are observed. (C) Percentage of ( $n = 189$ ), KO-1 ( $n$   
39 = 157) or KO-2 ( $n = 155$ ) cells showing cytokinesis failure was calculated, respectively.  
40 The  $P$  values were calculated using Student's  $t$ -test; \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .


41



42

43 **Figure S2 (related to Figure 1). Knockout of *NudCL2* causes an increase in**  
 44 **multinucleation in HeLa cells**


45 (A) Schematic representation of *NudCL2* gene targeting strategy. (B) Indel mutation of  
 46 the *NudCL2* DNA locus in *NudCL2* KO HeLa cells. The sgRNA target sites (underlined)  
 47 are indicated in red. The PAM sites are indicated in orange. TA cloning of PCR  
 48 products from genomic DNA extracted from WT and *NudCL2* KO cells (H-KO-1 and  
 49 H-KO-2). The green texts indicate base mutation (deletion) in the knockout cells. (C)  
 50 Western blot analysis of *NudCL2* protein in control and *NudCL2* KO cells.  $\beta$ -actin, a  
 51 loading control. (D) Control and *NudCL2* KO cells were stained with DAPI and anti-  
 52  $\alpha$ -tubulin antibody for immunofluorescence as described in Fig. 1J. The percentages of  
 53 multinucleated cells in WT ( $n = 864$ ), H-KO-1 ( $n = 638$ ) and H-KO-2 ( $n = 588$ ) were  
 54 calculated. Quantitative data are expressed as the mean  $\pm$  SD (from three biological  
 55 replicates). Student's *t*-test; \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ,



56

57 **Figure S3 (related to Figure 2). Loss of NudCL2 disrupts the localization of**  
 58 **Aurora B, PLK1 and MKLP1 at the midbody**

59 (A and B) Control and *NudCL2* KO HEK-293 cells were fixed and subjected to  
 60 immunofluorescence analysis with antibodies of Aurora B and  $\alpha$ -tubulin (A) or MKLP1  
 61 and PLK1 (B). The super-resolution microscopy images and three-dimensional (3D)  
 62 coordinate reconstructions showing the localization of Aurora B, PLK1 and MKLP1 at  
 63 the midbody. Representative image with views at XZ and YZ planes. DNA was  
 64 visualized with DAPI. Scale bars, 5  $\mu$ m. Higher magnifications of the boxed regions  
 65 are displayed.




66

67 **Figure S4 (related to Figure 2). Knockout of *NudCL2* disrupts the midbody**  
 68 **architecture in HeLa cells**

69 (A) Control and *NudCL2* KO cells were fixed and stained with DAPI, anti-Aurora B  
 70 and anti- $\alpha$ -tubulin antibodies for immunofluorescence as described in Fig. 2H. The  
 71 frequencies of WT ( $n = 102$ ), H-KO-1 ( $n = 105$ ) and H-KO-2 ( $n = 104$ ) cells with  
 72 Aurora B mislocalization at the midbody were calculated. H-KO-1/ WT: \*\*\*  $P =$   
 73 0.0001; H-KO-2/WT: \*\*  $P = 0.0026$ . (B, C) Control and *NudCL2* KO cells were fixed  
 74 and stained with anti-MKLP1 and anti-PLK1 antibodies for immunofluorescence as  
 75 described in Fig. 2J. The frequencies of cells with mislocalization of MKLP1 ( $n = 104,$   
 76 105, 105) or PLK1 ( $n = 103, 108, 106$ ) at the midbody were calculated. Quantitative  
 77 data are expressed as the mean  $\pm$  SD (from three biological replicates). Student's  $t$ -test;  
 78 \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .

79




80

81 **Figure S5 (related to Figure 3). Rapid downregulation of NudCL2 protein by**  
 82 **mAID system induces the decrease of RCC2 protein.**

83 The NudCL2 KO HEK-293 cells expressing OsTIR1-T2A-NudCL2-mAID were  
 84 synchronized into anaphase by thymidine-nocodazole blocking and releasing for 30  
 85 minutes. Then cells were treated with or without auxin and harvested immediately at  
 86 different time points, and subjected to western blot using the indicated antibodies. β-  
 87 actin, a loading control.

88




89

90 **Figure S6 (related to Figure 3). Knockout of NudCL2 decreases the stability of**  
 91 **RCC2 protein in HeLa cells**

92 (A) Western blot analysis of protein extracts from control and *NudCL2* KO cells using  
 93 the indicated antibodies. (B) Western blot analysis of protein extracts from control and  
 94 *NudCL2* KO cells transfected with or without Myc or Myc-NudCL2 vector with the  
 95 indicated antibodies. (C) Control and *NudCL2* KO-1 cells were treated with 100 µg/ml  
 96 CHX and subjected to western blot analysis using anti-RCC2 and anti-NudCL2  
 97 antibodies. β-actin, a loading control.

98




100

101 **Figure S7 (related to Figure 3). The protein of RCC2 co-localizes with its mRNA**  
 102 **and the puromycin signals at the midbody.**

103 (A) HeLa cells were fixed and subjected to single molecule RNA fluorescence in situ  
 104 hybridization (smFISH) to detect *RCC2* mRNA, then followed by immunofluorescence  
 105 analysis with anti-RCC2 antibody. (B and C) Cells labeled with puromycin for 30 min  
 106 were fixed and subjected to immunofluorescence analysis with the antibodies as shown.  
 107 DNA was visualized with DAPI. Scale bars, 5  $\mu$ m. Higher magnifications of the boxed  
 108 regions are displayed.

109




110

111 **Figure S8 (related to Figure 3). RCC2 protein may be mainly degraded by the**  
 112 **ubiquitin-dependent proteasome pathway in *NudCL2* KO cells.**

113 (A) Control and *NudCL2* KO HEK-293 cells were treated with 1, 10 or 25 μM MG132  
 114 for 6 h and subjected to western blot with the indicated antibodies. (B) WT or *NudCL2*  
 115 KO HEK-293 cells were transfected with Myc-RCC2 and Flag-Ub for 48 h, then treated  
 116 with 10 μM MG132 for 6 h and subjected to immunoprecipitation with anti-Myc  
 117 antibody followed by western blot analysis with the indicated antibodies. 5% of total  
 118 input is shown. (C and D) Control and *NudCL2* KO HEK-293 cells were treated with  
 119 10 μM MG132, 20 mM ammonium chloride (NH<sub>4</sub>Cl) (C), and 100 nM bafilomycin A1  
 120 (BafA1) (D) for 2 h, followed by western blot with the indicated antibodies. β-actin, a  
 121 loading control.

122

123




124

125 **Figure S9 (related to Figure 3). The localization of RCC2 and NudCL2 during**  
126 **mitosis.**

127 HEK-293 cells were fixed and subjected to immunofluorescence analysis with the  
128 indicated antibodies. DNA was visualized with DAPI. Scale bars, 5  $\mu$ m.

129




130

131 **Figure S10 (related to Figure 4). NudCL2 specifically interacts with Hsp90 and**  
 132 **RCC2.**

133 (A-C) Immunoprecipitation experiments were performed using anti-NudC (A), anti-  
 134 NudCL (B), or anti-RCC2 (C) antibodies, respectively, then followed by western blot  
 135 analyses using antibodies as shown. 5% of total input is shown.

136




137

138 **Figure S11 (related to Figure 5). The localization of Hsp90 during mitosis.**

139 HEK-293 cells were fixed and subjected to immunofluorescence analysis with the

140 indicated antibodies. DNA was visualized with DAPI. Scale bars, 5  $\mu$ m.

141




142

143 **Figure S12 (related to Figure 5). Inhibition of Hsp90 ATPase activity by RA**  
 144 **decreases the RCC2 protein at the midbody**

145 (A and B) HEK-293 cells treated with different concentrations of RA for 48 h (A) or  
 146 0.5 μM RA at the indicated time points (B) were subjected to western blot analyses with  
 147 the indicated antibodies. β-actin, a loading control. (C) Cells treated with 0.5 μM RA  
 148 for 48 h were subjected to immunofluorescence analysis with the indicated antibodies.

149 Scale bars, 5 μm.

150



151

152 **Figure S13 (related to Figure 6). Ectopically expressed Myc-RCC2 is able to**  
 153 **localize at the midbody in *NudCL2* KO cells**

154 The *NudCL2* KO HEK-293 cells were transfected with Myc or Myc-RCC2 for 48 h and  
 155 subjected to immunofluorescence analysis with anti-Myc and anti- $\alpha$ -tubulin antibodies.

156 DNA was visualized with DAPI. Scale bars, 5  $\mu$ m.

157

**Table S1 (related to Figure 3). List of the smFISH probes for the detection of *RCC2* mRNA.**

Number	Name	Sequence 5'-3'
1	RCC2-P1	gccgcccgcgccttctct
2	RCC2-P2	gttgcccagctcggctct
3	RCC2-P3	agctccaggccgtcctctg
4	RCC2-P4	ctcgggttcggtgatgacca
5	RCC2-P5	cttcaagtttgacgcgctcc
6	RCC2-P6	aagtgccctttgcactttg
7	RCC2-P7	tcgaccaatcaagtcccagt
8	RCC2-P8	cggttaagcagcttgctgtt
9	RCC2-P9	gccaggcaccatattctgtg
10	RCC2-P10	agcacacgagcccagacca
11	RCC2-P11	tcatttcgaccccagctcca
12	RCC2-P12	cgcccacatgctgcagacac
13	RCC2-P13	gagcccgtttccgtcaaggc
14	RCC2-P14	agctgccccatcttgttttc
15	RCC2-P15	tgtacattatctgcgcgggg
16	RCC2-P16	attatcactgaattcagc
17	RCC2-P17	aatagaggttctcttgacag
18	RCC2-P18	gagttgtgtcccagctgacc
19	RCC2-P19	tactctatccgctgtgcccg
20	RCC2-P20	atgaagatggcactcgcgg
21	RCC2-P21	acaggcagaatctgtccatc
22	RCC2-P22	gccacgtctcgtacaaccac
23	RCC2-P23	ccaggaccagcgtgtgggta
24	RCC2-P24	cggccatagccaccaaaggc
25	RCC2-P25	atctcatccttctgctctgc
26	RCC2-P26	gtcaaacagcttcaccagge

27	RCC2-P27	caggtgtaaccagcatagat
28	RCC2-P28	aacagaccacccacttcaact
29	RCC2-P29	cgcagaggtcctgcactgct
30	RCC2-P30	gctgctcttcccacaagcca
31	RCC2-P31	cagctgatggtgctctcatc
32	RCC2-P32	ccccgtagcccagttcccga
33	RCC2-P33	tccagagtctttacctctg
34	RCC2-P34	ccatggcgacctgctctgag
35	RCC2-P35	tcattcttgcatacaccga
36	RCC2-P36	ggttcgggggttgattctg
37	RCC2-P37	tgcacatggaaatgacagct
38	RCC2-P38	aaattcctcgtttgacttcc
39	RCC2-P39	cggaacctcagggagtcta
40	RCC2-P40	ggtagttaacgttgatcat
41	RCC2-P41	ggactttgaaagcatacag
42	RCC2-P42	aatcaactatgagcaagta
43	RCC2-P43	acctagattgctcaaagttt
44	RCC2-P44	acgatgctaattgtaactgg
45	RCC2-P45	ctcttccatgtggcatctgc

159 **Dataset S1 (separate file related to Figure 3). Quantitative proteomic analysis in**  
160 **WT, *NudCL2* KO-1 and *NudCL2* KO-2 HEK-293 cells**

161 Quantitative proteomic analysis based on the isobaric tags for relative and absolute  
162 quantitation (iTRAQ) labeling in WT, *NudCL2* KO-1 and *NudCL2* KO-2 HEK-293  
163 cells.

164

165 **Dataset S2 (separate file related to Figure 3). List of the midbody proteins of**  
166 **human selected from MiCroKiTS 4.0 database**

167 The list of the midbody proteins of human selected from MiCroKiTS 4.0 database  
168 (<http://microkit.biocuckoo.org/>).